Literature DB >> 11095651

CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.

Alexandre Persu1, Olivier Devuyst1, Nathalie Lannoy2, Roland Materne3, Godela Brosnahan4, Patricia A Gabow4, Yves Pirson1, Christine Verellen-Dumoulin2.   

Abstract

Disease-modifying genes might participate in the significant intrafamilial variability of the renal phenotype in autosomal dominant polycystic kidney disease (ADPKD). Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is a chloride channel that promotes intracystic fluid secretion, and thus cyst progression, in ADPKD. The hypothesis that mutations of the CF gene, which encodes CFTR, might be associated with a milder renal phenotype in ADPKD was tested. A series of 117 unrelated ADPKD probands and 136 unaffected control subjects were screened for the 12 most common mutations and the frequency of the alleles of the intron 8 polymorphic TN: locus of CF. The prevalence of CF mutations was not significantly different in the ADPKD (1.7%, n = 2) and control (3.7%, n = 5) groups. The CF mutation was DeltaF508 in all cases, except for one control subject (1717-1G A). The frequencies of the 5T, 7T, and 9T intron 8 alleles were also similar in the ADPKD and control groups. Two additional patients with ADPKD and the DeltaF508 mutation were detected in the families of the two probands with CF mutations. Kidney volumes and renal function levels were similar for these four patients with ADPKD and DeltaF508 CFTR (heterozygous for three and homozygous for one) and for control patients with ADPKD collected in the University of Colorado Health Sciences Center database. The absence of a renal protective effect of the homozygous DeltaF508 mutation might be related to the lack of a renal phenotype in CF and the variable, tissue-specific expression of DeltaF508 CFTR. Immunohistochemical analysis of a kidney from the patient with ADPKD who was homozygous for the DeltaF508 mutation substantiated that hypothesis, because CFTR expression was detected in 75% of cysts (compared with <50% in control ADPKD kidneys) and at least partly in the apical membrane area of cyst-lining cells. These data do not exclude a potential protective role of some CFTR mutations in ADPKD but suggest that it might be related to the nature of the mutation and renal expression of the mutated CFTR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095651     DOI: 10.1681/ASN.V11122285

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  8 in total

Review 1.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

2.  Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.

Authors:  Murali K Yanda; Boyoung Cha; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

3.  Decreased renal accumulation of aminoglycoside reflects defective receptor-mediated endocytosis in cystic fibrosis and Dent's disease.

Authors:  Claudia Raggi; Kunio Fujiwara; Teresinha Leal; François Jouret; Olivier Devuyst; Sara Terryn
Journal:  Pflugers Arch       Date:  2011-09-17       Impact factor: 3.657

Review 4.  Polycystic kidney disease: pathogenesis and potential therapies.

Authors:  Vinita Takiar; Michael J Caplan
Journal:  Biochim Biophys Acta       Date:  2010-12-10

Review 5.  CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis.

Authors:  François Jouret; Olivier Devuyst
Journal:  Pflugers Arch       Date:  2008-10-07       Impact factor: 3.657

6.  c-JUN n-Terminal Kinase (JNK) Signaling in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Abigail O Smith; Julie A Jonassen; Kenley M Preval; Roger J Davis; Gregory J Pazour
Journal:  J Cell Signal       Date:  2022

Review 7.  Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.

Authors:  Thomas Bais; Ron T Gansevoort; Esther Meijer
Journal:  Drugs       Date:  2022-07-19       Impact factor: 11.431

8.  Gender-Dependent Phenotype in Polycystic Kidney Disease Is Determined by Differential Intracellular Ca2+ Signals.

Authors:  Khaoula Talbi; Inês Cabrita; Rainer Schreiber; Karl Kunzelmann
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.